Literature DB >> 19786139

Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis.

Elizabeth A Ruckdeschel1, Aimee L Brauer, Antoinette Johnson, Timothy F Murphy.   

Abstract

Moraxella catarrhalis is a respiratory tract pathogen causing otitis media in children and respiratory tract infections in adults with chronic obstructive pulmonary disease. This study examined two newly identified proteins as potential vaccine antigens. Antisera raised to recombinant purified proteins Msp22 and Msp75 recognized corresponding native proteins in multiple strains of M. catarrhalis. Vaccine formulations individually administered subcutaneously and intranasally showed enhanced clearance of M. catarrhalis in a mouse pulmonary clearance model by both routes of administration. Msp22 and Msp75 are antigenically conserved proteins that induce potentially protective immune responses and should be examined further as vaccine antigens for M. catarrhalis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19786139      PMCID: PMC2783942          DOI: 10.1016/j.vaccine.2009.09.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

Review 1.  Global burden of COPD: risk factors, prevalence, and future trends.

Authors:  David M Mannino; A Sonia Buist
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

Review 2.  Infection in the pathogenesis and course of chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Timothy F Murphy
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

3.  Human antibody response to outer membrane protein G1a, a lipoprotein of Moraxella catarrhalis.

Authors:  Diana G Adlowitz; Sanjay Sethi; Paul Cullen; Ben Adler; Timothy F Murphy
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  An aerosol challenge mouse model for Moraxella catarrhalis.

Authors:  W G Hu; J Chen; F M Collins; X X Gu
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

5.  Moraxella catarrhalis outer membrane protein CD elicits antibodies that inhibit CD binding to human mucin and enhance pulmonary clearance of M. catarrhalis in a mouse model.

Authors:  Dai-Fang Liu; John C McMichael; Steven M Baker
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

Review 6.  COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity.

Authors:  David M Mannino
Journal:  Chest       Date:  2002-05       Impact factor: 9.410

7.  Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model.

Authors:  Pablo D Becker; Gustavo M Bertot; David Souss; Thomas Ebensen; Carlos A Guzmán; Saúl Grinstein
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

Review 8.  Moraxella catarrhalis, a human respiratory tract pathogen.

Authors:  Timothy F Murphy; G Iyer Parameswaran
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

9.  Mining the Moraxella catarrhalis genome: identification of potential vaccine antigens expressed during human infection.

Authors:  Elizabeth A Ruckdeschel; Charmaine Kirkham; Alan J Lesse; Zihua Hu; Timothy F Murphy
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

Review 10.  Vaccines for mucosal immunity to combat emerging infectious diseases.

Authors:  F W van Ginkel; H H Nguyen; J R McGhee
Journal:  Emerg Infect Dis       Date:  2000 Mar-Apr       Impact factor: 6.883

View more
  14 in total

1.  Genome analysis of Moraxella catarrhalis strain BBH18, [corrected] a human respiratory tract pathogen.

Authors:  Stefan P W de Vries; Sacha A F T van Hijum; Wolfgang Schueler; Kristian Riesbeck; John P Hays; Peter W M Hermans; Hester J Bootsma
Journal:  J Bacteriol       Date:  2010-05-07       Impact factor: 3.490

2.  Role of the oligopeptide permease ABC Transporter of Moraxella catarrhalis in nutrient acquisition and persistence in the respiratory tract.

Authors:  Megan M Jones; Antoinette Johnson; Mary Koszelak-Rosenblum; Charmaine Kirkham; Aimee L Brauer; Michael G Malkowski; Timothy F Murphy
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

Review 3.  Potential impact of a Moraxella catarrhalis vaccine in COPD.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

Review 4.  Panel 5: Microbiology and immunology panel.

Authors:  Timothy F Murphy; Tasnee Chonmaitree; Stephen Barenkamp; Jennelle Kyd; Johanna Nokso-Koivisto; Janak A Patel; Terho Heikkinen; Noboru Yamanaka; Pearay Ogra; W Edward Swords; Tania Sih; Melinda M Pettigrew
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

5.  Mapping Protective Regions on a Three-Dimensional Model of the Moraxella catarrhalis Vaccine Antigen Oligopeptide Permease A.

Authors:  Antonia C Perez; Antoinette Johnson; Ziqiang Chen; Gregory E Wilding; Michael G Malkowski; Timothy F Murphy
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

6.  Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen.

Authors:  Min Yang; Antoinette Johnson; Timothy F Murphy
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

7.  A Cation-Binding Surface Protein as a Vaccine Antigen To Prevent Moraxella catarrhalis Otitis Media and Infections in Chronic Obstructive Pulmonary Disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Antoinette Johnson; Gregory E Wilding; Mary Koszelak-Rosenblum; Michael G Malkowski
Journal:  Clin Vaccine Immunol       Date:  2017-09-05

Review 8.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

Review 9.  A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

10.  The Vaccine Candidate Substrate Binding Protein SBP2 Plays a Key Role in Arginine Uptake, Which Is Required for Growth of Moraxella catarrhalis.

Authors:  Taketo Otsuka; Charmaine Kirkham; Aimee Brauer; Mary Koszelak-Rosenblum; Michael G Malkowski; Timothy F Murphy
Journal:  Infect Immun       Date:  2015-11-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.